IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
29.04
-0.44 (-1.49%)
At close: Apr 28, 2026, 4:00 PM EDT
29.44
+0.40 (1.38%)
After-hours: Apr 28, 2026, 5:01 PM EDT
IDEAYA Biosciences Employees
IDEAYA Biosciences had 145 employees as of December 31, 2025. The number of employees increased by 14 or 10.69% compared to the previous year.
Employees
145
Change (1Y)
14
Growth (1Y)
10.69%
Revenue / Employee
$1,508,345
Profits / Employee
-$784,124
Market Cap
2.55B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Beam Therapeutics | 511 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
| Disc Medicine | 155 |
IDYA News
- 7 days ago - IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 15 days ago - IDEAYA Biosciences Transcript: Study result - Transcripts
- 15 days ago - Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results - Barrons
- 15 days ago - IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PRNewsWire
- 18 days ago - IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - PRNewsWire
- 22 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire